• 1. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 2. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 3. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 4. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 5. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804

Recent Advances in the Study of 2-Amino-6-iodoquinazolin-4(1H)-one (CAS: 900475-01-6) in Chemical Biology and Pharmaceutical Research

The compound 2-Amino-6-iodoquinazolin-4(1H)-one (CAS: 900475-01-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential as a versatile scaffold for drug discovery. This quinazolinone derivative exhibits unique structural features that make it an attractive candidate for the development of novel therapeutic agents, particularly in oncology and infectious diseases. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic pathways, and exploring its biological activities.

One of the key areas of interest is the role of 2-Amino-6-iodoquinazolin-4(1H)-one as a kinase inhibitor. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is implicated in various diseases, including cancer. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent inhibitory activity against EGFR (Epidermal Growth Factor Receptor) and HER2 (Human Epidermal Growth Factor Receptor 2), two kinases frequently overexpressed in solid tumors. The study highlighted the compound's ability to induce apoptosis in cancer cell lines, suggesting its potential as a lead compound for targeted cancer therapies.

In addition to its anticancer properties, recent research has explored the antimicrobial potential of 2-Amino-6-iodoquinazolin-4(1H)-one. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported its efficacy against drug-resistant bacterial strains, including MRSA (Methicillin-Resistant Staphylococcus aureus). The study attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, a mechanism distinct from that of conventional antibiotics. This finding opens new avenues for the development of next-generation antimicrobial agents to combat the growing threat of antibiotic resistance.

The synthetic accessibility of 2-Amino-6-iodoquinazolin-4(1H)-one has also been a focus of recent investigations. Researchers have developed novel, high-yield synthetic routes that improve the scalability and cost-effectiveness of production. A 2023 paper in Organic Process Research & Development described a one-pot synthesis method that reduces the number of purification steps while maintaining high purity (>98%). This advancement is crucial for facilitating further preclinical and clinical studies of the compound and its derivatives.

Looking ahead, the future research directions for 2-Amino-6-iodoquinazolin-4(1H)-one include structure-activity relationship (SAR) studies to optimize its pharmacological properties, as well as investigations into its potential applications in other therapeutic areas such as neurodegenerative diseases and autoimmune disorders. The compound's unique chemical structure and demonstrated biological activities position it as a promising candidate for continued exploration in drug discovery and development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)